With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.149057-19-2,4-((Benzyloxy)carbonyl)-1-(tert-butoxycarbonyl)piperazine-2-carboxylic acid,as a common compound, the synthetic route is as follows.
Stage 1: 4-Benzyl 1 -tert-butyl 2-cyclopentyl piperazi ne-i ,2,4-tricarboxylate 4-[(Benzyloxy)carbonyl]- 1 -(tert-butoxycarbonyl)piperazi ne-2-carboxylic acid (9.96 g, 27 mmol) was dissolved in DCM (50 mL) and cooled to 0CC. Cyclopentanol (7.4 mL, 82 mmol), EDO (7.86 g, 41 mmol) and DMAP (0.33 g, 2.7 mmol) were then added and the reaction allowed to warm to RT, and stirred for 24 hrs. Water (100 mL) and DCM (50 mL) were then added and the layers separated. The aqueous layer was reextracted with DCM (2 x 50 mL) and the combined organic layers were then dried over Mg504 and concentrated in vacuo. Purification by column chromatography (40% EtOAc/heptane) afforded the title compound as a colourless oil (10.4 g, 88%). LCMS: m/z 455 [M+Na]., 149057-19-2
The synthetic route of 149057-19-2 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; CHROMA THERAPEUTICS LTD; DAVIES, Stephen John; PINTAT, Stephane; NORTH, Carl Leslie; MOFFAT, David Festus Charles; WO2014/1802; (2014); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics